MSKCC Update in Hematology and Medical Oncology 2026

Description

Include: 47 videos + 47 file sub vtt + 49 pdfs, size: 15.81 GB

Target Audience: hematologists and medical oncologists

1. Overview

The Memorial Sloan Kettering Cancer Center 2026 Update in Hematology and Medical Oncology and 14th Annual Board Review is a four-day comprehensive course offering an in-depth, current review of the diagnosis, staging, and management of neoplastic diseases across both solid tumors and hematologic malignancies. Expert-led lectures cover a wide spectrum of disease-specific topics, including gastrointestinal, gynecologic, thoracic, head and neck, genitourinary, soft tissue and skin, and central nervous system oncology, in addition to hematologic oncology.

Course Date: Friday, March 13, 2026, 9:10 AM – Monday, March 16, 2026, 4:00 PM, Online

This course is designed for medical oncology professionals — including physicians, nurses, pharmacists, advanced practice providers, fellows, and residents — seeking a comprehensive update in Medical Oncology and Hematology.

2. Learning Objectives

1. Define state-of-the-science in diagnosis, staging, and therapeutic management of solid tumor cancers and hematologic cancers
2. Discuss recent treatment advances in solid tumor and hematologic oncology and apply knowledge gained in modern clinical practice
3. Prepare for ABIM examinations in medical oncology and hematology

3. Target Audience

Best for hematologists and medical oncologists who want comprehensive updates on the management of hematologic malignancies and solid tumors.

4. Topics

1. Acute Lymphocytic Leukemia

2. Acute Myeloid Leukemia

3. Anal and Rectal Cancers

4. Anticoagulation- Update on an Evolving Field

5. Apporach to the Bleeding Patient

6. Auto _Allo

7. Breast Cancer- Radiation Therapy

8. Breast Cancer- Surgery

9. CAR T Cell

10. Carcinoma of Unknown Primary

11. Central Nervous System Tumors

12. Chronic Lymphocytic Leukemia _Small Lymphocytic Lymphoma

13. Chronic Myelogenous Leukemia

14. Clinical Indications for Use of Blood Products and Associated Risks

15. Colon Cancer

16. Diffuse Large B-Cell Lymphoma _Mantle Cell Lymphoma _Burkitt Lymphoma

17. Esophageal and Gastric Cancers

18. Head and Neck, Thyroid, and Non-Melanoma Skin Cancers

19. Hemolytic Anemia

20. Hepatocellular Cancer and Cholangiocarcinoma

21. HER2-Positive Breast Cancer

22. Hereditary Cancer Genetics

23. Hodgkin Lymphoma_T Cell

24. Hormone Receptor-Positive Breast Cancer

25. Infectious Disease

26. Kidney Cancer

27. Low-Grade Non-Hodgkin Lymphoma

28. Melanoma

29. Mesothelioma

30. Myelodysplastic

31. Myeloma_Amyloid

32. Myeloproliferative Neoplasms

33. Non-Small Cell Lung Cancer

34. Ovarian Cancer

35. Pancreatic and Neuroendocrine Cancers

36. Pharmacology I_II

37. Prostate Cancer

38. Sarcoma

39. Sickle Cell Disease, Thalassemia

40. Small Cell Lung Cancer

41. Testis Cancer

42. Thrombocytopenia and ITP

43. Thrombotic Disorders

44. Transfusion Reactions

45. Triple-Negative Breast Cancer

46. Urothelial Cancer

47. Uterine, Cervix, and Other Gynecologic Cancers

48. 2026 Post-Test HemOnc Board Review